Human Domain Antibodies against Virulence Traits of Candida albicans Inhibit Fungus Adherence to Vaginal Epithelium and Protect against Experimental Vaginal Candidiasis

Antibody variable domains (domain antibodies [DAbs]) are genetically engineered antibody fragments that include individual heavy-chain (VH) or κ-chain (Vκ) variable domains and lack the Fc region. Human DAbs against the 65-kDa mannoprotein (MP65) or the secretory aspartyl proteinase (SAP)–2 of Candi...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases Vol. 195; no. 1; pp. 149 - 157
Main Authors: De Bernardis, Flavia, Liu, Haiqun, O’Mahony, Rachel, La Valle, Roberto, Bartollino, Silvia, Sandini, Silvia, Grant, Steven, Brewis, Neil, Tomlinson, Ian, Basset, Rachel C., Holton, John, Roitt, Ivan M., Cassone, Antonio
Format: Journal Article
Language:English
Published: Chicago, IL The University of Chicago Press 01-01-2007
University of Chicago Press
Oxford University Press
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antibody variable domains (domain antibodies [DAbs]) are genetically engineered antibody fragments that include individual heavy-chain (VH) or κ-chain (Vκ) variable domains and lack the Fc region. Human DAbs against the 65-kDa mannoprotein (MP65) or the secretory aspartyl proteinase (SAP)–2 of Candida albicans (monospecific DAbs) or against both fungal antigens (heterodimeric, bispecific DAbs) were generated from phage expression libraries. Both monospecific and bispecific DAbs inhibited fungus adherence to the epithelial cells of rat vagina and accelerated the clearance of vaginal infection with the fungus. When heterodimeric DAbs were used, the clearance of infection was at least equivalent to treatment with fluconazole. The in vivo protective effects of DAbs were demonstrated by both pre- and postchallenge schedules of DAb administration and with both fluconazole-susceptible and fluconazole-resistant strains of C. albicans. This is the first demonstration that human DAbs lacking the Fc constituent can efficiently control an infection and can act largely by inhibiting adherence
Bibliography:istex:31B62153C6E89F61BE9D334B9EC07D0D4AA385EC
ark:/67375/HXZ-34939RF8-4
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-1899
1537-6613
DOI:10.1086/509891